Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs
European Journal of Immunology · 2025
DOI: 10.1002/eji.202451676 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Immunology, 2025. Verfasst von Antara Mondal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nano-Biotechnology Laboratory, National Institute of Immunology, New Delhi, India. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Immunotherapy, Adoptive, Antigen-Presenting Cells, Melanoma, Experimental. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Department of Biotechnology, Government of India, Ramalingaswami Re-entry Fellowship, Department of Biotechnology, Government of India, Science & Engineering Research Board (SERB), Government of India.
Abstract (Originalsprache)
Adoptive T‐cell therapy is an emerging immunotherapeutic strategy for treating cancer, but the compromised quality of CD8+ T‐cells limits the therapeutic efficacy. Traditional methods involving polyclonal expansion of CD8+ T‐cells mainly prioritize yielding a high quantity of CD8+ T‐cells. However, the antigen‐specificity of ex vivo expanded CD8+ T‐cells and the ability to produce cytolytic molecules are the two critical determinants of therapeutic efficacy that remain poorly studied. To address this problem, we formulated nanoscale artificial antigen‐presenting cells (a‐APCs) displaying tumor‐specific class‐I peptide‐major histocompatibility complexes (p‐MHC‐I) and co‐stimulatory molecules to expand the antigen‐specific CD8+ T‐cells ex vivo. We found that the magnitude of ex vivo expanded T‐cells was directly proportional to the valency of p‐MHC coated on the a‐APCs. Promisingly, a‐APC with higher valency of p‐MHC yielded CD8+ T‐cells capable of producing a greater extent of cytolytic molecules such as granzyme B and perforin, exhibited excellent therapeutic efficacy by inhibiting the growth of aggressive murine melanoma than the CD8+ T‐cells expanded by lower valency a‐APCs. Our findings emphasize that the valency of p‐MHC is a critical parameter for configuring nanoscale a‐APCs, which governs ex vivo manufacturing of therapeutically potent antigen‐specific CD8+ T‐cells capable of inhibiting the growth of solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nano-Biotechnology Laboratory, National Institute of Immunology, New Delhi, India.
Förderung
- Department of Biotechnology, Government of India
- Ramalingaswami Re-entry Fellowship, Department of Biotechnology, Government of India
- Science & Engineering Research Board (SERB), Government of India
- Indian Council of Medical Research, Government of India
- National Institute of Immunology.
Zitieren
APA
Mondal, A., Jamal, F., Das, A., Sahoo, A. K., Chaudhary, K., Chowdhury, S., Jha, A., & Singha, S. (2025). Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs. European Journal of Immunology. https://doi.org/10.1002/eji.202451676
Vancouver
Mondal A, Jamal F, Das A, Sahoo AK, Chaudhary K, Chowdhury S, et al. Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs. European Journal of Immunology. 2025. doi:10.1002/eji.202451676
BibTeX
@article{Mondal2025,
author = {Mondal, Antara and Jamal, Faisal and Das, Arpita and Sahoo, Arnab Kumar and Chaudhary, Khushboo and Chowdhury, Sarmili and Jha, Aakriti and Singha, Santiswarup},
title = {Inhibition of Melanoma Growth by Ex Vivo Expanded Tumor‐Specific CD8+ T Cells Is Dependent on the Configuration of Nanoscale Artificial APCs},
journal = {European Journal of Immunology},
year = {2025},
doi = {10.1002/eji.202451676}
}
EUVIMED